Development of Medical Countermeasures for Biothreat Agents, Antimicrobial-Resistant Infections an Emerging Infectious Diseases
Award Notice Posted
- Solicitation number
- HHS-NIH-NIAID-BAA2021-1
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Awarded
- to Intravacc B.V.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N93022C00058 Federal contract award
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institute of Allergy and Infectious Diseases awarded INTRAVACC B.V. a $14,613,141 cost-reimbursement contract for the development of medical countermeasures for biothreat agents, antimicrobial-resistant infections and emerging infectious diseases. The contract was awarded under full and open competition on September 21, 2022, for an unspecified period of performance, to develop countermeasures against biothreats, drug-resistant infections and new diseases.
Notice text
This cost-reimbursement contract award was made under full and open competition. This type of contract was selected because costs cannot be adequately defined at the time of contract award.
Awarded contract 75N93022C00058 to INTRAVACC B.V. for 14613141.00 on 2022-09-21.
Notice history
6 of 9 notices listed here. See the rest on GovTribe.
Similar open opportunities
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity